Merck KGaA Sponsored ADR (MKKGY) AI Stock Analysis

Company Guidance

For full year 2026, Merck expects organic group net sales growth of 3% to 4%, foreign exchange impact of minus 1% to 0%, group net sales of around EUR 21.5 billion to EUR 21.9 billion, group EBITDA pre of EUR 6.2 billion to EUR 6.4 billion, organic EBITDA pre growth of 3% to 5%, and EPS pre of EUR 8.30 to EUR 8.70; Life Science organic sales growth is expected between 6% and 7%, with EBITDA pre organic growth in a range of 6% to 8%, Healthcare organic net sales development of minus 3% to minus 2% and EBITDA pre of around EUR 2.9 billion to EUR 3 billion, and Electronics organic net sales growth of 10% to 11%, EBITDA pre of around EUR 1.1 billion and organic EBITDA pre growth of 33% to 35%. Process Solutions is expected to deliver organic growth around mid-single digits in Q4, with full-year 2026 growth in the upper end of the 8% to 12% range and a book-to-bill ratio above 1; the midterm outlook for Process Solutions remains 8%, 12% organic growth in the range for 2027, while Discovery Solutions should assume a low single-digit organic growth. As of 2027, the underlying tax rate is expected to be in the range of 22% to 24%, Healthcare EBITDA pre margin is expected to remain north of 30%, and Life Science and Electronics could see 30% already next year.